Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

BACKGROUND: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT without causing hypercalcemia and hyperphosphatemia. However, there is significant inter-individual response variance to cinac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drug Des Devel Ther
Main Authors: Jeong, Sohyun, Kim, In-Wha, Oh, Kook-Hwan, Han, Nayoung, Joo, Kwon Wook, Kim, Hyo Jin, Oh, Jung Mi
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944925/
https://ncbi.nlm.nih.gov/pubmed/27468225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S103370
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados